Mustang Bio Announces First Data From Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy; Iniital Data Show Clinical Responses From Four Of Four Indolent Lymphoma Patients
Author: Benzinga Newsdesk | August 16, 2023 08:03am